本帖最后由 老马 于 2012-1-13 21:20 编辑
9 Q, M: Y: A! j+ k6 H
$ f6 k0 C B; l爱必妥和阿瓦斯丁的比较" j* z0 Z8 L }8 B6 V1 u3 h
s- ]- ~7 d; n) i7 t# Q
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" F8 ~3 n0 ^6 g0 \& |$ I& ?
8 E' @/ r: N# R3 H/ W, g
& h( {2 V3 w" A( P: P! ahttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/0 _. j( }: a7 f' e/ i9 Q# O
==================================================
* a2 Y( o* J4 g5 I/ c0 P% gOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
?8 W4 J- e6 b9 y; I. ` z2 YPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.9 m& J' f+ [- R/ L1 d0 U
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( l6 E" f5 @- B. g6 U X" \
|